Loading stock data...

Gland Pharma Limited

NSE: GLAND BSE: GLAND

NSE
1,928.90 23.10 (1.21%)

Prev Close

1905.8

Open Price

1918.9

Volume

71,417

Today Low / High

1907.8 / 1947.7

52 WK Low / High

1277.8 / 2131

Range

1,832 - 2,025

BSE
1,927.95 15.25 (0.80%)

Prev Close

1912.7

Open Price

1912.95

Volume

2,811

Today Low / High

1908.25 / 1948.75

52 WK Low / High

1200 / 2130

Range

1,832 - 2,024

The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1928.9 (target range: 1,832 - 2,025), reflecting a change of 23.1 (1.21209%). On the BSE, it is listed at 1927.95 (target range: 1,832 - 2,024), showing a change of 15.25 (0.7973%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.

30 Oct 1,903.90 -0.17%
29 Oct 1,910.00 -0.29%
28 Oct 1,925.00 -1.17%
27 Oct 1,941.40 -1.20%
24 Oct 1,925.00 0.85%
23 Oct 1,937.90 -0.30%
21 Oct 1,937.80 -0.79%
20 Oct 1,931.20 -0.33%
17 Oct 1,923.60 0.74%
16 Oct 1,924.00 -0.33%
15 Oct 1,910.10 1.38%
14 Oct 1,925.00 -0.22%
13 Oct 1,924.00 0.24%
10 Oct 1,951.00 -1.41%
09 Oct 1,955.00 -0.11%
08 Oct 1,937.80 0.99%
07 Oct 1,940.50 -0.01%
06 Oct 1,953.00 -0.69%
03 Oct 1,960.10 -0.44%

Gland Pharma Limited Graph

Gland Pharma Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges

If you are looking for the target price for Gland Pharma Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,928.90, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.

Scenario Price Target Range
Bullish Scenario 1,927.95 1,947.23 1,752.51 - 2,141.95
1,966.51 1,573.21 - 2,359.81
1,985.79 1,390.05 - 2,581.53
Bearish Scenario 1,927.95 1,908.67 1,717.80 - 2,099.54
1,889.39 1,511.51 - 2,267.27
1,870.11 1,309.08 - 2,431.14

Overview of Gland Pharma Limited

ISIN

INE068V01023

Industry

Drug Manufacturers - General

Vol.Avg

208,737

Market Cap

313,152,533,196

Last Dividend

18

Official Website

Visit Website

IPO Date

2020-11-20

DCF Diff

-264.26

DCF

2,169

Financial Ratios Every Investor Needs

Stock Dividend of GLAND

Date Label Adj Dividend Dividend Record Date Payment Date Declaration Date
2025-08-14 August 14, 25 18 18 2025-08-14 2025-09-27
2024-08-16 August 16, 24 20 20 2024-08-16 2024-09-29

Stock Rating Details for GLAND

Metric Value Recommendation
Overall Rating B- Sell
DCF Score 4 Buy
ROE Score 3 Neutral
ROA Score 1 Strong Sell
Debt-to-Equity (DE) Score 1 Strong Sell
Price-to-Earnings (PE) Score 2 Sell
Price-to-Book (PB) Score 3 Neutral

Annual Financial Income Report

Date Revenue Co.Rev GP GPR R&D Expenses G&A Expenses Operating Income Net Income EPS EBITDA NIR
2025-03-31 5,616.50 Cr 2,462.13 Cr 3,154.37 Cr 0.5616 0.00 Cr 0.00 Cr 1,737.76 Cr 698.53 Cr 42.40 1,231.40 Cr 0.1244
2024-03-31 5,664.72 Cr 2,553.91 Cr 3,110.81 Cr 0.5492 0.00 Cr 0.00 Cr 1,822.57 Cr 772.46 Cr 46.90 1,296.81 Cr 0.1364
2023-03-31 3,624.60 Cr 1,859.46 Cr 1,765.14 Cr 0.4870 201.40 Cr 0.00 Cr 1,156.86 Cr 781.04 Cr 47.44 1,031.00 Cr 0.2155
2022-03-31 4,400.71 Cr 2,249.42 Cr 2,151.29 Cr 0.4889 227.30 Cr 0.00 Cr 1,583.97 Cr 1,211.66 Cr 73.81 1,510.15 Cr 0.2753
2021-03-31 3,462.88 Cr 1,609.67 Cr 1,853.21 Cr 0.5352 122.00 Cr 0.00 Cr 1,418.75 Cr 996.96 Cr 63.07 1,302.02 Cr 0.2879

Annual Financials Balance Sheet

Date C&C Equ. Tot. Assets Tot. Liab. Stock. Equity Tot. Debt Net Debt Inv. PP&E (Net) Curr. Def. Rev. Non-Curr. Def. Rev. LT Invest. Curr. Liab.
2025-03-31 2,556.21 Cr 11,224.92 Cr 2,074.18 Cr 9,150.7410 Cr 313.73 Cr -2,242.48 Cr 1,685.22 Cr 3,943.89 Cr 0.00 Cr 41.39 Cr 0.00 Cr 1,564.8450 Cr
2024-03-31 357.09 Cr 10,661.25 Cr 1,937.40 Cr 8,723.8430 Cr 372.17 Cr 15.08 Cr 1,676.33 Cr 3,871.00 Cr 85.38 Cr 40.49 Cr -925.75 Cr 1,398.3630 Cr
2023-03-31 1,908.90 Cr 8,777.54 Cr 818.81 Cr 7,958.7220 Cr 4.45 Cr -1,904.44 Cr 1,978.19 Cr 1,736.10 Cr 76.04 Cr 4.99 Cr -73.37 Cr 729.1330 Cr
2022-03-31 315.82 Cr 7,833.62 Cr 676.00 Cr 7,157.6210 Cr 4.74 Cr -311.08 Cr 1,229.19 Cr 1,726.90 Cr 33.92 Cr 5.55 Cr 202.21 Cr 582.0250 Cr
2021-03-31 491.82 Cr 6,496.08 Cr 592.84 Cr 5,903.2420 Cr 5.00 Cr -486.83 Cr 1,288.17 Cr 1,324.44 Cr 28.69 Cr 0.00 Cr -1,947.73 Cr 512.5280 Cr

Annual Financials Cash Flow Statement

Date Operating Cash Investing Cash Financing Cash Free Cash Cash Change Cash at End CapEx Income Debt Repay Dividends Inventory
2025-03-31 914.7300 Cr 1,704.7360 Cr -433.4760 Cr 530.1880 Cr 2,199.1210 Cr 2,556.2090 Cr -384.5420 Cr 698.5260 Cr -75.8810 Cr -329.4880 Cr -19.9180 Cr
2024-03-31 996.7970 Cr -1,756.9110 Cr -799.4160 Cr 606.8670 Cr -1,551.8070 Cr 357.0880 Cr -389.9300 Cr 772.4600 Cr -756.2780 Cr 0.0000 Cr 666.0770 Cr
2023-03-31 363.9680 Cr 1,208.1880 Cr 14.9190 Cr 140.8490 Cr 1,590.0750 Cr 1,908.8950 Cr -223.1190 Cr 1,054.5820 Cr -0.1120 Cr 0.0000 Cr -759.6330 Cr
2022-03-31 790.7690 Cr -1,002.6210 Cr 34.8980 Cr 268.6500 Cr -173.6430 Cr 318.8200 Cr -522.1190 Cr 1,618.5520 Cr -0.1360 Cr 0.0000 Cr 89.5010 Cr
2021-03-31 604.9290 Cr -1,524.0000 Cr 1,238.4600 Cr 376.1530 Cr 322.9660 Cr 492.4630 Cr -228.7760 Cr 1,334.8100 Cr -0.8910 Cr 0.0000 Cr -518.8890 Cr

Quarterly Financial Income Report

Date Revenue Co.Rev GP GPR Operating Income Net Income EPS EBITDA NIR
2025-06-30 1,505.62 Cr 566.79 Cr 938.83 Cr 0.6236 484.79 Cr 215.48 Cr 13.08 356.53 Cr 0.1431
2025-03-31 1,424.91 Cr 713.15 Cr 711.76 Cr 0.4995 181.44 Cr 186.54 Cr 11.32 322.65 Cr 0.1309
2024-12-31 1,384.05 Cr 517.37 Cr 866.68 Cr 0.6262 480.13 Cr 204.69 Cr 12.42 344.96 Cr 0.1479
2024-09-30 1,405.83 Cr 620.84 Cr 785.00 Cr 0.5584 405.89 Cr 163.53 Cr 9.93 296.13 Cr 0.1163
2024-06-30 1,401.71 Cr 610.78 Cr 790.94 Cr 0.5643 386.51 Cr 143.76 Cr 8.73 258.58 Cr 0.1026

Quarterly Financials Balance Sheet

Date Cash & Equiv. Short-Term Inv. Cash & Short-Term Net Receivables Inventory Total Curr. Assets PP&E (Net) Total Assets Total Liabilities
2025-06-30 0.00 Cr 0.00 Cr 2,952.21 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr -9,150.74 Cr
2025-03-31 2,556.21 Cr 396.00 Cr 3,049.83 Cr 1,516.53 Cr 1,685.22 Cr 6,782.94 Cr 3,943.89 Cr 11,224.92 Cr 2,074.18 Cr
2024-12-31 0.00 Cr 0.00 Cr 2,820.11 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr -8,788.00 Cr
2024-09-30 2,820.11 Cr 110.28 Cr 2,820.11 Cr 1,489.97 Cr 1,577.03 Cr 6,404.15 Cr 3,932.79 Cr 10,866.89 Cr 2,078.89 Cr
2024-06-30 -1,839.43 Cr 3,678.86 Cr 1,839.43 Cr 0.00 Cr 0.00 Cr 1,839.43 Cr 0.00 Cr 0.00 Cr -8,723.84 Cr

Quarterly Financials Cash Flow Statement

Date Net Income Operating Cash Flow Investing Cash Flow Financing Cash Flow Net Cash Change Cash at End Cash at Beginning CapEx Free Cash Flow
2025-06-30 215.48 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2025-03-31 186.54 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-12-31 204.69 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-09-30 163.53 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-06-30 143.76 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr

Splits History

Date Label Split Ratio
No split history data available.

Similar Stocks: Drug Manufacturers - General

Company Name Symbol Price Market Cap Volume
Cipla Limited CIPLA ₹1,501.30 ₹1,212,697,785,165.00 ₹3,364,682.00
Abbott India Limited ABBOTINDIA ₹28,995.00 ₹616,123,482,495.00 ₹11,667.00
GlaxoSmithKline Pharmaceuticals Limited GLAXO ₹2,618.60 ₹443,606,640,632.00 ₹92,281.00
Gland Pharma Limited GLAND ₹1,928.90 ₹317,798,664,325.00 ₹71,417.00
Pfizer Limited PFIZER ₹5,209.00 ₹238,299,753,673.00 ₹11,476.00
Sanofi Consumer Healthcare India Ltd. SANOFICONR ₹4,842.60 ₹111,528,090,097.00 ₹5,647.00
Sanofi India Limited SANOFI ₹4,780.60 ₹110,097,218,000.00 ₹17,560.00
Marksans Pharma Limited MARKSANS ₹182.08 ₹82,512,054,872.00 ₹607,046.00
Senores Pharmaceuticals Ltd. SENORES ₹771.20 ₹35,516,527,066.00 ₹102,809.00

Key Executives

Head of Domestic Marketing
Mr. Surinder Koul

Gender: male

Year Born:

Chief Executive Officer
Mr. Shyamakant Giri

Gender: male

Year Born:

Senior Vice President of R&D
Mr. R.V.R. Prabhakara Sastry

Gender: male

Year Born:

Chief Financial Officer
Mr. Ravi Shekhar Mitra

Gender: male

Year Born: 1977

Chief Financial Controller
Mr. Rong Wu

Gender: male

Year Born:

Executive Chairman
Mr. Srinivas Sadu

Gender: male

Year Born: 1969

Company Secretary & Vice-President of Compliance & CSR
Mr. Sampath Kumar Pallerlamudi

Gender: male

Year Born: 1981

Chief Operating Officer
Mr. Satnam Singh Loomba

Gender: male

Year Born: 1968

Head of Quality
Mr. K Raghuramachandra Rao

Gender: male

Year Born:

FAQs about Gland Pharma Limited

Who is the CEO of the company?

The CEO is Shyamakant Giri.

What is the current market price of the stock?

The current price is ₹1,900.70.

What is the 52-week price range?

The range is ₹1277.8-2131.

What is the market capitalization of the company?

The market capitalization is ₹31,315.25 crores.

What is the dividend yield?

The dividend yield is 0.95%.

What is the Price-to-Earnings (P/E) ratio?

The P/E ratio is 40.65.

Which sector does the company belong to?

The company operates in the Healthcare sector.

What does the company do?

Overview of Gland Pharma Limited (ISIN: INE068V01023) is a leading Drug Manufacturers - General in India. With a market capitalization of ₹31,315.25 crores and an average daily volume of 208,737 shares, it operates in the Drug Manufacturers - General. The company last declared a dividend of ₹18.